Subscribe or Manage Preferences
With $137 billion and growing spent on treatment in the US healthcare system annually, cancer care delivery poses a significant challenge. At a special session at ASH 2015 on new payment models, Michael Kolodziej, MD, National Medical Director for Oncology [ Read More ]
Managing medical decision-making has become big business. Over the past few years, “clinical pathways” have become one of the most common tools for medical decision-making in oncology. Until recently, the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN [ Read More ]
The multikinase inhibitor midostaurin is the first targeted therapy to improve overall survival (OS) in patients with acute myeloid leukemia (AML) and the FLT3 mutation. Midostaurin plus standard chemotherapy improved survival compared with placebo plus chemotherapy as an upfront treatment [ Read More ]
The American Society of Hematology (ASH) released 5 new recommendations for hematology-related tests and procedures to avoid, based on recommendations from other medical societies that are often adopted into each organization’s Choosing Wisely program. These 5 new recommendations have now [ Read More ]
Ibrutinib (Imbruvica) significantly reduced the risk for disease progression or death compared with standard treatment with chlorambucil (Leukeran) in older (aged ≥65 years) treatment-naïve patients with chronic lymphocytic leukemia (CLL). Ibrutinib achieved a 91% reduction in the risk for disease [ Read More ]
This detailed article of codes related to kidney cancer is intended to assist practice managers and other healthcare providers and payers to ensure their proper use of coding and billing information associated with the treatment of patients with kidney cancer, [ Read More ]
The regular use of aspirin reduces the incidence of and risk for death from lethal prostate cancer according to the results of a large observational study reported at the 2016 ASCO Genitourinary Cancers Symposium. For the purposes of this study, [ Read More ]
A liquid biopsy using phlebotomy blood samples can identify phenotypes and genomic characteristics of circulating tumor cells that may personalize treatment selection for men with advanced prostate cancer, according to the results of a study presented by Howard I. Scher, [ Read More ]
The following studies represent a selection of key clinical trials that are currently recruiting patients with kidney cancer, including renal-cell carcinoma, for inclusion in investigations of new therapies or new combinations of available therapies for patients with kidney cancer. Each [ Read More ]
Congress closed out 2015 with a bang, passing a number of large, end-of-year spending bills to keep the government funded through 2016, as well as several provisions that will impact cancer care. Before the end of 2015, President Obama signed [ Read More ]
There is an urgent unmet need for more effective therapies in pancreatic cancer. The American Cancer Society estimated that approximately 49,000 new cases of pancreatic cancer will be diagnosed in the United States in 2015, and more than 40,500 people [ Read More ]
Last month we introduced the topic of the US Pharmacopeia Convention (USP)’s “General Chapter 800 Hazardous Drugs—Handling in Healthcare Settings” (USP 800), with the first article in this series. In this month’s article, I’d like to share with you our [ Read More ]